Vitrase (hyaluronidase Injection) Ovine, 200 USP Units/mL

vitrase

Vitrase (hyaluronidase for injection) is the first and only pure, preservative-free, thimerosal-free, ovine hyaluronidase. 

Vitrase is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Vitrase is the only hyaluronidase preparation approved by the U.S. Food and Drug Administration for uses at concentrations >150 USP units/mL. 

Vitrase is available in 200 USP Units/mL vials in sterile solution. 

To order:


Call: 877.520.0500 opt 2
Email: Medicisorders@mckesson.com
Fax: 800.567.7485

If you have questions about the utility of Vitrase in specific procedures please call 1-800-385-7034.

Warnings, Precautions, Adverse Reactions

  • Discontinue Vitrase (hyaluronidase injection) if sensitization occurs.
  • Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
  • Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.
  • Hyaluronidase should not be used to reduce the swelling of bites or stings.
  • Hyaluronidase should not be applied directly to the cornea.
  • Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.
  • Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.

When considering the administration of any other drug with hyaluronidase, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug. Patients receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines may require larger doses of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase.

The most frequently reported adverse experiences have been local injection site reactions. Hyaluronidase has been reported to enhance the adverse events associated with co-administered drugs products. Allergic reactions (urticaria, angiodema) have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.

Please click here(48.7 KB, PDF) to view the Vitrase full Prescribing Information.

US/LGX/12/0052(1)

Learn More